Inceptua Group, Author at Inceptua Group

Elevar Therapeutics Inc. Announces Licensing Agreement with Inceptua Group for Commercialization of Apealea® (Paclitaxel Micellar) in Europe

Elevar Therapeutics Inc. Announces Licensing Agreement with Inceptua Group for Commercialization of Apealea® (Paclitaxel Micellar) in Europe December 28 2020, Elevar Therapeutics, Inc, a fully integrated biopharmaceutical company built…

Inceptua GroupDecember 28, 2020

Featured Press release

Inceptua Partners with Global Blood Therapeutics for an Early Access Program for Voxelotor for Patients with Sickle Cell Disease

LUXEMBOURG, Dec. 3, 2020 Inceptua announces that the company has entered into a partnership with Global Blood Therapeutics, Inc. (GBT), a biopharmaceutical company focused on discovering, developing and delivering treatments…

Inceptua GroupDecember 3, 2020

Clinical Trial Services Featured

Webinar: Strategic Comparator Sourcing in China

Optimizing the Clinical Supply Chain China is now the second-largest pharmaceutical market in the world, and with a more harmonized and efficient clinical trial approval process, it is seeing a…

Inceptua GroupNovember 30, 2020

Clinical Trial Services Featured

Safely and Reliably Supplying your Comparator Needs during COVID19

Maintaining Safe and Reliable Supply of Comparators during COVID19 As an agile, well-distributed and robust global supplier of Comparators for the biopharmaceutical industry, Inceptua is uniquely positioned to safely and…

Inceptua GroupNovember 2, 2020

Medicines Access

Maintaining access to your medicines during COVID19

As an agile, global, and robust provider of medicines access programs for the biopharmaceutical industry, Inceptua is uniquely positioned to safely and reliably supply your products throughout the global crisis.…

Inceptua GroupNovember 2, 2020

Featured Press release

Inceptua receives approval of marketing authorization transfer of Jetrea® (ocriplasmin) for the treatment of symptomatic vitreomacular adhesion

LUXEMBOURG – 25 September, 2020 – Inceptua Group – pharmaceutical company and service partner announces that the European Commission (EC) has approved the transfer of the marketing authorisation for Jetrea®…

Inceptua GroupSeptember 25, 2020

Featured Press release

Inceptua Group Announces Partnership with BioCryst on Expanded Access Program for Patients with Hereditary Angioedema

LUXEMBOURG – June 26, 2020 –Inceptua Group – pharmaceutical company and service partner spanning throughout the product lifecycle – from clinical trial comparator sourcing, packaging, labelling, and distribution solutions, through…

Inceptua GroupJune 26, 2020

Featured Press release

Global License Agreement a Building Block in Strategic Growth Plans

LUXEMBOURG – 23 March, 2020 – Inceptua – pharmaceutical company and service partner - and biopharmaceutical company Oxurion have announced a global license agreement for the commercialization of JETREA®, a…

Inceptua GroupMarch 23, 2020

Clinical Trial Services Featured

How we are supporting with uninterrupted supply of medicines for clinical trials

In clinical trials, a Comparator drug, either an investigational or marketed product, is often required to determine the efficacy relative to a drug that is already on the market. Safe,…

Inceptua GroupMarch 22, 2020

Featured Press release

Oxurion and Inceptua Group enter global license agreement for the commercialization of JETREA®

Press release: Oxurion and Inceptua Group enter global license agreement for the commercialization of JETREA® Oxurion announces the signing of a JETREA® global license agreement with Inceptua Group. JETREA® is…

Inceptua GroupMarch 13, 2020